Lower risk of heart failure, cardiovascular disease and overall mortality in patients with type 2 diabetes following initiation of SGLT2 inhibitors

The article Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis, recently published in Lancet Diabetes & Endocrinology,  shows that the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in normal clinical practice is associated with lower risk of heart failure, cardiovascular disease and overall mortality, compared with the use of other glucose-lowering drugs used for type 2 diabetes.

Read More »

Annual Report 2016

The 2016 annual report shows a striking and steady increase in the number and quality of publications from clinical and basic science. Another striking trend is the increased international collaboration. Several of our researchers also play prominent roles in national and international organizations promoting education, research and improved care for patients with diabetes. 

Please click here to read Oslo Diabetes Research Centre’s Annual Report 2016.

 

  

Annual Research Seminar, March 9-10, 2017

ODFS_logo
The annual research seminar of Oslo Diabetes Research Centre gathered researchers from ten different research groups at Thorbjørnrud, March 9-10, 2017. Our researchers assembled to share their experiences in two days of lectures. Ongoing projects, unpublished data and research in progress were discussed. We were also delighted to welcome the invited speakers: Marcel den Hoed, Assistant professor at Uppsala University,  and Bjørn Olav Åsvold, Associate professor at NTNU .

Read More »